Immune Retraining to Slow Type 1 Diabetes Progression
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This early-stage trial tests a combination approach to help your immune system stop attacking insulin-producing cells in newly diagnosed type 1 diabetes. It aims to preserve your body's ability to make insulin and slow disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Recently diagnosed with type 1 diabetes (within 6 months)
- Age 18–45 years old
- Your pancreas still produces some insulin (measurable C-peptide)
- No immunosuppressive medications in the past 3 months
- No active infections (HIV, hepatitis, tuberculosis) or recent cancer
- Willing to use contraception and avoid pregnancy during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two medicines, teplizumab and ATG, to see if they can delay or prevent type 1 diabetes from progressing to needing insulin. It is for people ages 4 to 35 who have early signs of diabetes (stage 2) and specific autoantibodies.
This study tests whether teplizumab can help keep the body making insulin in people recently diagnosed with type 1 diabetes. It is for children and young adults aged 1 to 25, and compares the drug against a placebo.
This trial tests an experimental drug called teplizumab to see if it can slow down or stop type 1 diabetes from getting worse. It is for Japanese people aged 1 to 34 who have stage 2 type 1 diabetes (blood sugar is slightly abnormal but not yet full diabetes).
This trial tests whether giving your own regulatory T cells (a type of immune cell) back to you can help slow or stop the immune attack on your pancreas in type 1 diabetes. It is for people aged 8 to 65 who still make some insulin.
This study tests whether a shingles vaccine (Shingrix) combined with a diabetes medication (a GLP-1 agonist) can help preserve your pancreas's ability to make insulin when you've recently been diagnosed with type 1 diabetes. The goal is to slow down the autoimmune attack on your insulin-producing cells.
This study tests two different medications (Anti-Thymocyte Globulin and Adalimumab or Verapamil) to see if they can slow down the loss of insulin production in people with newly diagnosed type 1 diabetes. Participants will be randomly assigned to receive one of the treatments and will be followed for about a year to see how well their bodies still make insulin.
Hear when a new Autoimmune Diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.